Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.

The FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Volumn 18, Issue 3, 2004, Pages 565-567

  Devy, Laetitia ^a   de Groot, Franciscus M H ^a   Blacher, Silvia ^a   Hajitou, Amin ^a   Beusker, Patrick H ^a   Scheeren, Hans W ^a   Foidart, Jean Michel ^a   Noël, Agnès ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; DRUG DERIVATIVE; PLASMIN; PRODRUG; ST 9802; ST 9905; TUMOR PROTEIN; UROKINASE;

ADENOCARCINOMA; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOTRANSFORMATION; BODY WEIGHT; BREAST TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; MAXIMUM TOLERATED DOSE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE; VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; BIOTRANSFORMATION; BODY WEIGHT; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PLASMIN; PRODRUGS; URINARY PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2442715459     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.03-0462fje     Document Type: Article

References (0)